Andreas Norlin - Ascelia Pharma Chief Officer
| ACE Stock | SEK 2.90 0.11 3.65% |
Insider
Andreas Norlin is Chief Officer of Ascelia Pharma AB
| Phone | 46 735 179 118 |
| Web | https://www.ascelia.com |
Ascelia Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3347) % which means that it has lost $0.3347 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.537) %, meaning that it generated substantial loss on money invested by shareholders. Ascelia Pharma's management efficiency ratios could be used to measure how well Ascelia Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Marcuss | Cantargia AB | N/A | |
| Harald Borgeke | BioArctic AB | N/A | |
| Kjell Sjstrm | Cantargia AB | N/A | |
| Frida Lekander | BioArctic AB | N/A | |
| Anita BCom | Saniona AB | 55 | |
| Jorgen Drejer | Saniona AB | 68 | |
| Sren Bregenholt | Alligator Bioscience AB | 52 | |
| Christer Mller | BioArctic AB | 64 | |
| Palle MS | Saniona AB | 65 | |
| MBA MSc | Saniona AB | 63 | |
| Julie Silber | Alligator Bioscience AB | N/A | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Malin Carlsson | Alligator Bioscience AB | 55 | |
| Janus Larsen | Saniona AB | 51 | |
| Sumeet MD | Alligator Bioscience AB | N/A | |
| Johanna Flting | BioArctic AB | 51 | |
| Ignacio GarciaRibas | Cantargia AB | N/A | |
| Gunilla Andersson | BioArctic AB | 62 | |
| Karin Nielsen | Saniona AB | N/A | |
| Marie Svensson | Alligator Bioscience AB | 59 | |
| Katja Margell | Hansa Biopharma AB | N/A | |
Management Performance
| Return On Equity | -0.54 | |||
| Return On Asset | -0.33 |
Ascelia Pharma AB Leadership Team
Elected by the shareholders, the Ascelia Pharma's board of directors comprises two types of representatives: Ascelia Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascelia. The board's role is to monitor Ascelia Pharma's management team and ensure that shareholders' interests are well served. Ascelia Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascelia Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carl MD, Chief Officer | ||
| Julie Brogren, Deputy Officer | ||
| Magnus Corfitzen, Chief Officer | ||
| Despina Hedin, Chief Officer | ||
| Mikael Widell, Head Communications | ||
| Andreas Norlin, Chief Officer |
Ascelia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ascelia Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 359.6 M | |||
| Shares Outstanding | 33.67 M | |||
| Shares Owned By Insiders | 22.73 % | |||
| Shares Owned By Institutions | 31.16 % | |||
| Price To Book | 2.34 X | |||
| EBITDA | (129.45 M) | |||
| Net Income | (125.9 M) | |||
| Cash And Equivalents | 219.15 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ascelia Stock Analysis
When running Ascelia Pharma's price analysis, check to measure Ascelia Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascelia Pharma is operating at the current time. Most of Ascelia Pharma's value examination focuses on studying past and present price action to predict the probability of Ascelia Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascelia Pharma's price. Additionally, you may evaluate how the addition of Ascelia Pharma to your portfolios can decrease your overall portfolio volatility.